Somewhat Positive News Coverage Somewhat Unlikely to Impact aTyr Pharma (LIFE) Stock Price
Headlines about aTyr Pharma (NASDAQ:LIFE) have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. aTyr Pharma earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.3265540045663 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s scoring:
- 13G Filing: Viking Global and aTyr Pharma Inc (LIFE) (feedproxy.google.com)
- 13G Filing: EcoR1 Capital and aTyr Pharma Inc (LIFE) (insidermonkey.com)
- Piper Jaffray Companies Begins Coverage on aTyr Pharma, Inc. (LIFE) (americanbankingnews.com)
- Zacks Investment Research Lowers aTyr Pharma, Inc. (LIFE) to Hold (americanbankingnews.com)
- aTyr Pharma, Inc. (LIFE) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
A number of research firms have recently weighed in on LIFE. BMO Capital Markets reiterated a “hold” rating on shares of aTyr Pharma in a report on Wednesday, May 24th. ValuEngine upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a report on Saturday, July 8th. Zacks Investment Research upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a report on Wednesday, July 12th. Finally, Piper Jaffray Companies began coverage on shares of aTyr Pharma in a report on Thursday, September 7th. They set an “overweight” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $4.27.
Shares of aTyr Pharma (NASDAQ:LIFE) traded up 6.56% during mid-day trading on Wednesday, reaching $3.25. 84,709 shares of the company’s stock traded hands. aTyr Pharma has a 12-month low of $2.10 and a 12-month high of $4.45. The firm’s market capitalization is $77.48 million. The stock has a 50-day moving average price of $3.03 and a 200 day moving average price of $3.46.
aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06. Analysts anticipate that aTyr Pharma will post ($2.18) EPS for the current fiscal year.
In other aTyr Pharma news, CEO John Mendlein purchased 37,736 shares of the stock in a transaction dated Thursday, August 31st. The stock was purchased at an average price of $2.65 per share, with a total value of $100,000.40. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Paul Schimmel purchased 94,336 shares of the stock in a transaction dated Thursday, August 31st. The stock was acquired at an average cost of $2.65 per share, with a total value of $249,990.40. Following the transaction, the director now directly owns 40,440 shares in the company, valued at approximately $107,166. The disclosure for this purchase can be found here. 33.30% of the stock is owned by insiders.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.